Endometrial cancer recurrent
Not recruitingA Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy
A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy
- Disease:Endometrial cancer recurrent
- Substances:PaclitaxelDoxorubicin Hydrochloride+1
France- Participants:18–64 years · 65+ years
- Substances:Paclitaxel
- Sponsor:Gilead Sciences Inc.











